Interleukin-23 Antagonist

Interleukin-23 Antagonists

Psoriasis

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION </h1><p class="First">Tildrakizumab-asmn is a humanized IgG1/k antibody that specifically binds to the p19 subunit of interleukin-23 (IL-23).</p><p>Tildrakizumab-asmn is produced in a recombinant Chinese hamster ovary (CHO) cell line and has an approximate molecular mass of 147 kilodaltons.</p><p>ILUMYA (tildrakizumab-asmn) injection, for subcutaneous use, is a sterile, clear to slightly opalescent, colorless to slightly yellow solution. ILUMYA is supplied in a single-dose prefilled syringe with a glass barrel and 29-gauge fixed, 1/2-inch needle.</p><p>The syringe is fitted with a passive needle guard and a needle cover.</p><p>Each 1 mL single-dose prefilled syringe contains 100 mg of tildrakizumab-asmn formulated in: L-histidine (0.495 mg), L-histidine hydrochloride monohydrate (1.42 mg), polysorbate 80 (0.5 mg), sucrose (70.0 mg), and Water for Injection, USP with a pH of 5.7-6.3.</p></section>

Ilumya | Compass Oncology

Does Compass Oncology work closely with Ilumya and Sun Pharmaceutical Industries, Inc.?

Does Compass Oncology offer services for Ilumya patients?

What conditions does Compass Oncology support?

How does Compass Oncology help with insurance?